Cohance Lifesciences Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot. Further, the company has informed the Exchange regarding voting results.
COHANCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Cohance Lifesciences shareholders have approved all five resolutions in the postal ballot, with voting closing on June 13, 2026. The key resolution was the appointment of Mr. Umang Vohra (DIN: 02296740) as Chairman (effective May 1, 2026) and Group CEO (effective May 20, 2026), which passed with 99.62% support. Shareholders also approved his remuneration in excess of Section 197 limits with 88.57% in favor. Additionally, the 'Cohance Lifesciences Limited – Employee Stock Option Plan, 2026' was approved with 96.57% support, along with its extension to unlisted subsidiaries (96.64%) and the grant of stock options equal to or exceeding 1% of issued capital in a year (88.16%). Overall, about 89.4% of total shares were polled, with promoter group voting unanimously in favor of all resolutions.
This formalizes Umang Vohra's leadership transition at Cohance Lifesciences, bringing in a high-profile external CEO and enabling a new ESOP framework to attract and retain talent. Shareholders have largely backed management's plans, though institutional investors showed notable dissent on the CEO's excess remuneration and the large ESOP grants.